Skip to main content

Table 5 Multivariate analysis of factors associated with LTFU among HIV-infected adults on antiretroviral therapy

From: Factors associated with 36-month loss to follow-up and mortality outcomes among HIV-infected adults on antiretroviral therapy in Central Kenya

 Multivariate Results (n = 23890)
6 months12 months24 months36 months
aOR (95% CI)P valueaOR (95% CI)P valueaOR (95% CI)P valueaOR (95% CI)P value
Gender
 Male1.23 (1.12–1.36)< 0.0011.19 (1.10–1.29)< 0.0011.19 (1.1–1.27)< 0.0011.19 (1.12–1.27)< 0.001
 FemaleRef Ref Ref Ref 
BMI
  < 18.51.52 (1.3–1.78)< 0.0012.51 (1.88–3.36)< 0.0012.02 (1.63–2.5)< 0.0011.68 (1.39–2.02)< 0.001
 18.5–24.9Ref Ref Ref Ref 
 25–29.90.58 (0.43–0.77)< 0.0010.61 (0.49–0.77)< 0.0010.66 (0.55–0.79)< 0.0010.69 (0.6–0.79)< 0.001
 30+0.50 (0.37–0.69)< 0.0010.55 (0.42–0.71)< 0.0010.62 (0.52–0.75)< 0.0010.69 (0.58–0.82)< 0.001
Age
 20–351.23 (1.12–1.35)< 0.0011.36 (1.26–1.47)< 0.0011.47 (1.37–1.57)< 0.0011.49 (1.40–1.59)< 0.001
 36–50Ref Ref Ref Ref 
 51+1.03 (0.88–1.2)0.7191.00 (0.87–1.14)0.9600.98 (0.87–1.1)0.6650.99 (0.89–1.10)0.803
Marital Status
 Single1.34 (1.19–1.51)< 0.0011.31 (1.18–1.45)< 0.0011.26 (1.15–1.38)< 0.0011.34 (1.23–1.45)< 0.001
 Divorced1.35 (1.19–1.53)< 0.0011.31 (1.17–1.46)< 0.0011.30 (1.19–1.43)< 0.0011.25 (1.15–1.36)< 0.001
 MarriedRef Ref Ref Ref 
 Widowed1.01 (0.87–1.18)0.8590.99 (0.87–1.12)0.8141.02 (0.91–1.14)0.7261.03 (0.93–1.14)0.555
CD4
 0–2501.34 (1.16–1.55)< 0.0011.33 (1.17–1.5)< 0.0011.15 (1.05–1.27)0.0041.18 (1.08–1.29)< 0.001
 251–500Ref Ref Ref Ref 
 Above 5001.42 (0.81–2.49)0.2151.22 (0.73–2.05)0.4481.42 (0.93–2.16)0.1021.33 (0.90–1.96)0.149
Regimen Started
 D4T-basedRef Ref Ref Ref 
 ABC-based2.37 (1.82–3.08)< 0.0012.44 (1.93–3.09)< 0.0012.33 (1.87–2.90)< 0.0012.17 (1.75–2.69)< 0.001
 AZT-based0.74 (0.65–0.83)< 0.0010.75 (0.67–0.83)< 0.0010.78 (0.71–0.85)< 0.0010.85 (0.79–0.93)< 0.001
 TDF-based0.62 (0.55–0.69)< 0.0010.67 (0.61–0.74)< 0.0010.73 (0.68–0.8)< 0.0010.86 (0.80–0.92)< 0.001
Baseline WHO Stage
 Stage IRef Ref Ref Ref 
 Stage II1.03 (0.87–1.22)0.7321.08 (0.95–1.24)0.2421.07 (0.96–1.19)0.2511.07 (0.98–1.17)0.147
 Stage III1.34 (1.14–1.57)< 0.0011.31 (1.16–1.48)< 0.0011.25 (1.13–1.39)< 0.0011.22 (1.12–1.34)< 0.001
 Stage IV1.83 (1.48–2.26)< 0.0011.57 (1.31–1.88)< 0.0011.38 (1.17–1.62)< 0.0011.34 (1.15–1.57)< 0.001